<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23133592</article-id><article-id pub-id-type="pmc">3487782</article-id><article-id pub-id-type="publisher-id">PONE-D-12-25956</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0046736</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Genomics</subject></subj-group><subj-group><subject>Immunology</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Nutrition</subject></subj-group><subj-group><subject>Obstetrics and Gynecology</subject></subj-group></subj-group></article-categories><title-group><article-title>Pregnancy Induces Transcriptional Activation of the Peripheral Innate Immune System and Increases Oxidative DNA Damage among Healthy Third Trimester Pregnant Women</article-title><alt-title alt-title-type="running-head">Pregnancy Alters Genomic Marks in Blood Leukocytes</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Xinyin</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bar</surname><given-names>Haim Y.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Jian</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>West</surname><given-names>Allyson A.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Perry</surname><given-names>Cydne A.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Malysheva</surname><given-names>Olga V.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Devapatla</surname><given-names>Srisatish</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pressman</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vermeylen</surname><given-names>Francoise M.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wells</surname><given-names>Martin T.</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Caudill</surname><given-names>Marie A.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Division of Nutritional Sciences, Cornell University, Ithaca, New York, United States of America</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Cornell University Statistical Consulting Unit, Cornell University, Ithaca, New York, United States of America</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Department of Pediatrics, Cayuga Medical Center, Ithaca, New York, United States of America</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, New York, United States of America</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Department of Statistical Science, Cornell University, Ithaca, New York, United States of America</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Ansari</surname><given-names>Aftab A.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Emory University School of Medicine, United States of America</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>mac379@cornell.edu</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: XJ MAC. Performed the experiments: XJ JY AAW CAP OVM SD EP. Analyzed the data: HYB FV MTW. Wrote the paper: XJ MAC.</p></fn></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>2</day><month>11</month><year>2012</year></pub-date><volume>7</volume><issue>11</issue><elocation-id>e46736</elocation-id><history><date date-type="received"><day>22</day><month>8</month><year>2012</year></date><date date-type="accepted"><day>4</day><month>9</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; 2012 Jiang et al</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Jiang et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Pregnancy induces physiological adaptations that may involve, or contribute to, alterations in the genomic landscape. Pregnancy also increases the nutritional demand for choline, an essential nutrient that can modulate epigenomic and transcriptomic readouts secondary to its role as a methyl donor. Nevertheless, the interplay between human pregnancy, choline and the human genome is largely unexplored.</p></sec><sec><title>Methodology/Principal Findings</title><p>As part of a controlled feeding study, we assessed the influence of pregnancy and choline intake on maternal genomic markers. Healthy third trimester pregnant (n&#x0200a;=&#x0200a;26, wk 26&#x02013;29 gestation) and nonpregnant (n&#x0200a;=&#x0200a;21) women were randomized to choline intakes of 480 mg/day, approximating the Adequate Intake level, or 930 mg/day for 12-weeks. Blood leukocytes were acquired at study week 0 and study week 12 for microarray, DNA damage and global DNA/histone methylation measurements. A main effect of pregnancy that was independent of choline intake was detected on several of the maternal leukocyte genomic markers. Compared to nonpregnant women, third trimester pregnant women exhibited higher (<italic>P&#x0003c;0.05</italic>) transcript abundance of defense response genes associated with the innate immune system including pattern recognition molecules, neutrophil granule proteins and oxidases, complement proteins, cytokines and chemokines. Pregnant women also exhibited higher (<italic>P</italic>&#x0003c;0.001) levels of DNA damage in blood leukocytes, a genomic marker of oxidative stress. No effect of choline intake was detected on the maternal leukocyte genomic markers with the exception of histone 3 lysine 4 di-methylation which was lower among pregnant women in the 930 versus 480 mg/d choline intake group.</p></sec><sec><title>Conclusions</title><p>Pregnancy induces transcriptional activation of the peripheral innate immune system and increases oxidative DNA damage among healthy third trimester pregnant women.</p></sec></abstract><funding-group><funding-statement>This work was funded by the Egg Checkoff, through the Egg Nutrition Center; the Beef Checkoff, through the National Cattlemen's Beef Association and the Nebraska Beef Council; the United States Department of Agriculture Cooperative State Research, Education and Extension Service (CSREES), Special Research Grant No. 00444528; and the Affinito-Stewart Grants Program, through the President's Council of Cornell Women. The funding sources had no role in the study design, interpretation of the data and/or publication of the results.</funding-statement></funding-group><counts><page-count count="10"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Pregnancy induces several physiological adaptations to meet the needs of the developing fetus and the health requirements of the mother. Many of these pregnancy-induced physiologic adaptations may involve, or contribute to, alterations in the genomic landscape. Nevertheless, very few studies have examined the interplay between pregnancy and the human genome.</p><p>A prominent change during pregnancy is the modulation of the immune system to accommodate the presence of a semiallogeneic fetus <xref rid="pone.0046736-Wegmann1" ref-type="bibr">[1]</xref>. In normal pregnancy, there is a shift in the balance of T lymphocytes, mediators of the adaptive cellular immune response, towards a Th2 (immunosuppressive) phenotype with an anti-inflammatory cytokine profile. However, there is also a need to defend against pathogens for the mother-fetus dyad <xref rid="pone.0046736-Witkin1" ref-type="bibr">[2]</xref>. Neutrophils, mediators of the innate immune response that play a key role in the first line of defense against pathogens, increase in peripheral blood during pregnancy <xref rid="pone.0046736-Belo1" ref-type="bibr">[3]</xref>. Nevertheless, it is unclear as to whether these neutrophils are activated. <italic>In vitro</italic> studies showed that neutrophils from pregnant women exhibited reduced microbial killing and chemotaxis <xref rid="pone.0046736-Crocker1" ref-type="bibr">[4]</xref>, <xref rid="pone.0046736-Crouch1" ref-type="bibr">[5]</xref>. However, flow cytometry studies showed that several neutrophil surface markers were higher in the pregnant state indicating neutrophil activation <xref rid="pone.0046736-Luppi1" ref-type="bibr">[6]</xref>, <xref rid="pone.0046736-Sacks1" ref-type="bibr">[7]</xref>. Thus, studies that profile the transcriptome of blood leukocytes are needed to better understand the status of the immune system during human pregnancy.</p><p>A greater susceptibility to oxidative stress, mostly because of the mitochondria-rich placenta <xref rid="pone.0046736-Casanueva1" ref-type="bibr">[8]</xref>, is another characteristic of human pregnancy. Oxidative stress can cause DNA damage <xref rid="pone.0046736-Furness1" ref-type="bibr">[9]</xref>, which in turn can lead to aberrant gene expression and apoptosis. Although higher levels of DNA damage are detected among women with complicated pregnancies <xref rid="pone.0046736-Furness1" ref-type="bibr">[9]</xref>, <xref rid="pone.0046736-Harma1" ref-type="bibr">[10]</xref>, it is unclear whether DNA damage is elevated in normal pregnancy. Studies that examine indicators of DNA damage are needed to advance understanding of redox balance during normal pregnancy and to inform nutritional therapeutic opportunities.</p><p>Pregnancy is also associated with an increased demand for methyl donors to maintain epigenetic marks in the expanding maternal and fetal tissues <xref rid="pone.0046736-Zeisel1" ref-type="bibr">[11]</xref>. DNA and histone methylation play a fundamental role in regulating chromatin structure, stability, and gene expression <xref rid="pone.0046736-Kass1" ref-type="bibr">[12]</xref>, <xref rid="pone.0046736-Cheung1" ref-type="bibr">[13]</xref>. A major source of methyl groups for DNA and histone methylation is the essential micronutrient choline, which is recommended at an intake level of 450 mg/d during pregnancy <xref rid="pone.0046736-Institute1" ref-type="bibr">[14]</xref>. Notably, we previously demonstrated in third trimester pregnant women that consumption of choline at approximately two times the current intake recommendation (i.e., 930 versus 480 mg/d) substantially altered epigenetic marks <xref rid="pone.0046736-Jiang1" ref-type="bibr">[15]</xref> and transcriptome readouts (unpublished data) in fetal derived tissues (i.e., placental and cord blood leukocytes). Nonetheless, it remains to be determined if a maternal choline intake exceeding current recommendations can alter genomic marks in the mothers themselves.</p><p>The aims of the current study were to investigate the influence of both pregnancy and maternal choline intake on leukocyte genomic markers. To accomplish these aims, we examined genome-wide gene expression, DNA damage, and global DNA/histone methylation in blood leukocytes obtained from third trimester pregnant women and nonpregnant control women enrolled in a 12-week controlled feeding study <xref rid="pone.0046736-Yan1" ref-type="bibr">[16]</xref>.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Study Participants</title><p>Healthy third trimester (week 26&#x02013;29 gestation) singleton pregnant women and nonpregnant control women aged &#x02265;21 y were recruited from Ithaca, New York, and surrounding areas between January 2009 and October 2010. Entry into the study was contingent upon good health status, no tobacco or alcohol use, and a willingness to comply with the study protocol. Twenty-six of the 29 pregnant women and 21 of the 22 nonpregnant women who started the study completed it. Information regarding the study participants and the CONSORT flowchart have been reported previously <xref rid="pone.0046736-Yan1" ref-type="bibr">[16]</xref>.</p></sec><sec id="s2b"><title>Description of procedures</title><sec id="s2b1"><title>Study Design and Diet</title><p>This was a 12-week controlled feeding study in which pregnant (n&#x0200a;=&#x0200a;26) and nonpregnant (n&#x0200a;=&#x0200a;21) women were randomized to either 480 (an intake level that approximates the choline adequate intake, AI) or 930 mg choline/d. The choline was derived from the diet (380 mg/d) plus supplemental choline chloride (either 100 or 550 mg choline/d for the 480 or 930 mg/d intake levels, respectively). Throughout the 12-wk study, the participants consumed a 7-day cycle menu. Choline-free prenatal multivitamins and docosahexaenoic acid supplements were provided daily as detailed in Yan et al <xref rid="pone.0046736-Yan1" ref-type="bibr">[16]</xref>. The fact that all participants consumed the same diet and supplements makes this study particularly suitable to examining the effects of pregnancy on a wide-array of genomic and metabolic endpoints.</p></sec><sec id="s2b2"><title>Sample collection</title><p>Blood samples were obtained at study-baseline (week 0) and study-end (week 12). Fasting (10-h) peripheral blood mononuclear cells (PBMC, including lymphocytes and monocytes) samples were retrieved with Vacutainer CPT tubes (BD, Franklin Lakes, NJ); whole blood, leukocyte and plasma samples were retrieved with EDTA tubes (BD) as previously described <xref rid="pone.0046736-Yan1" ref-type="bibr">[16]</xref>, <xref rid="pone.0046736-Shin1" ref-type="bibr">[17]</xref>.</p></sec><sec id="s2b3"><title>Analytical measurements</title><p>
<italic>Complete blood counts</italic> were conducted with 1 mL whole blood using an AcT diff 2 hematology analyzer (Beckman Coulter, Brea, CA) according to the manufacturer's instructions.</p><p>
<italic>Total RNA purification</italic> was performed with a commercially available kit (RNeasy Mini kit, Qiagen, Valencia, CA) as previously detailed <xref rid="pone.0046736-Jiang1" ref-type="bibr">[15]</xref>. The integrity of the RNA samples was determined using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Only samples of an RNA Integrity Number (RIN) &#x0003e;8.0 were included for microarray. There were 12 sets (a set includes both a wk-0 and a wk-12 measurement) of samples from pregnant participants (n&#x0200a;=&#x0200a; 6/choline intake group) and 10 sets of samples from nonpregnant participants (n&#x0200a;=&#x0200a;5/choline intake group) that passed the RIN cutoff.</p><p>
<italic>Gene expression profiling</italic> was performed using the Whole Human Gene Expression Microarray 4&#x000d7;44 K (Agilent). Antisense RNA amplification and cyanine-3 labeling was performed with an Amino Allyl MessageAmp II aRNA amplification kit (Ambion Inc., Grand island, NY). Microarray hybridization was performed at 65&#x000b0;C for 17-h in an Agilent Microarray Hybridization oven. Microarray scanning was performed in an Agilent Scanner (G2505C) and the images were extracted using Agilent Feature Extraction Software 10.5. Data normalization was performed using log2 transformation and median normalization. An extension of the Laplace approximation EM Microarray Analysis (LEMMA) package based on the R software platform (<ext-link ext-link-type="uri" xlink:href="http://www.R-project.org">http://www.R-project.org</ext-link>) <xref rid="pone.0046736-R1" ref-type="bibr">[18]</xref> developed by Bar et al. <xref rid="pone.0046736-Bar1" ref-type="bibr">[19]</xref>, <xref rid="pone.0046736-Bar2" ref-type="bibr">[20]</xref> was used to detect differentially expressed genes. The version used here (unpublished data) can sensitively detect differentially expressed genes, as it takes into account not only mean differences, but also variational differences between the comparison groups. Using this method we were able to increase the number of discoveries of differentially expressed genes, relative to other methods that do not account for differential variation. The differentially expressed genes were declared by controlling the false discovery rate (FDR) with Benjamini-Hochberg (BH) correction &#x0003c;0.05 and expression fold difference &#x0003e;2. Differentially expressed genes were classified according to their gene ontology (GO) using High-Throughput GoMiner <xref rid="pone.0046736-Zeeberg1" ref-type="bibr">[21]</xref>. Hierarchical clustering was conducted with MultiExperiment Viewer <xref rid="pone.0046736-Saeed1" ref-type="bibr">[22]</xref>, <xref rid="pone.0046736-Saeed2" ref-type="bibr">[23]</xref>. Microarray results of select genes were verified using quantitative real-time PCR. All data is MIAME compliant. The data has been deposited in a MIAME compliant database NCBI's Gene Expression Omnibus <xref rid="pone.0046736-Edgar1" ref-type="bibr">[24]</xref> as detailed on the MGED Society website (<ext-link ext-link-type="uri" xlink:href="http://www.mged.org/Workgroups/MIAME/miame.html">http://www.mged.org/Workgroups/MIAME/miame.html</ext-link>) and are accessible through GEO Series accession number GSE36532 (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36532">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36532</ext-link>).</p><p>
<italic>Reverse transcription</italic> and <italic>quantitative real-time PCR</italic> were performed as previously described <xref rid="pone.0046736-Chew1" ref-type="bibr">[25]</xref>. Data are expressed using the delta delta Ct method <xref rid="pone.0046736-Livak1" ref-type="bibr">[26]</xref> and glyceraldehyde-3-phosphate dehydrogenase (<italic>GAPDH</italic>) is used as the housekeeping gene.</p><p>
<italic>Circulating tumor necrosis factor alpha (TNF&#x003b1;) and interleukin 6 (IL6)</italic> were measured in EDTA plasma with commercially available ELISA kits (R&#x00026;D systems, Minneapolis, MN) according to the manufacturer's instructions.</p><p>
<italic>Peripheral blood mononuclear cell (PBMC) DNA damage</italic> was measured in duplicate via the alkaline version of single-cell gel electrophoresis (COMET assay). Sample preparation was performed as described previously <xref rid="pone.0046736-Shin1" ref-type="bibr">[17]</xref>. DNA migration from the nucleus was visualized (75 cells/sample) with an Olympus BX-50 light microscope and a high resolution QImaging Retiga EXi cooled CCD camera. Photos were acquired using the MetaMorph Premier (ver. 7.0) software (Molecular Devices, Sunnyvale, CA) after staining with SYBR Gold fluorescent dye (Invitrogen, Grand Island, NY). Percent tail DNA (defined as the proportion of DNA that has migrated from the nucleus) was used as an index of DNA damage and was calculated using the software Komet 6.0 (Andor Technology, South Windsor, CT).</p><p>
<italic>Global DNA methylation</italic> was measured in leukocytes using liquid chromatography-tandem mass spectrometry (LC-MS/MS) as described by Song et al. <xref rid="pone.0046736-Song1" ref-type="bibr">[27]</xref> with modifications based on our instrumentation <xref rid="pone.0046736-Shin1" ref-type="bibr">[17]</xref>. Global DNA methylation [5-methyl-2&#x02032;-deoxycytidine (5mdC)] is expressed as a percentage of 2&#x02032;-deoxyguanosine (representing total 2&#x02032;-deoxycytidine).</p><p>
<italic>Global histone methylation</italic> was measured with western blots as described previously <xref rid="pone.0046736-Jiang1" ref-type="bibr">[15]</xref>. Leukocyte samples (200 &#x000b5;L) were suspended in 0.2 N hydrochloric acid at 4&#x000b0;C overnight. The extracts were separated by SDS-PAGE and transferred to Immobilon-FL polyvinylidene fluoride transfer membranes. Membranes were incubated with corresponding primary and secondary antibodies <xref rid="pone.0046736-Jiang1" ref-type="bibr">[15]</xref>. Target protein bands were quantified with the LI-COR Odyssey&#x000ae; imaging system (LI-COR, Lincoln, NE) and expressed as the ratio of intensity of the histone epigenetic mark to the reference total histone 3 proteins.</p></sec></sec><sec id="s2c"><title>Ethics</title><p>The study was approved by the Cornell University and Cayuga Medical Center Institutional Review Boards for Human Participants and written informed consent was obtained from every participant prior to study entry. The study was registered at clinicaltrials.gov as NCT01127022.</p></sec><sec id="s2d"><title>Statistical analysis</title><p>The effect of pregnancy on the dependent variables (e.g. DNA damage, epigenetic marks, gene expression) was assessed at study-baseline (wk-0) and study-end (wk-12) separately with general linear models (GLMs). Pregnancy status and choline intake were included as independent variables and all two-way interactions were tested. The effect of choline intake on the genomic markers was assessed at study-end in a similar manner with study-baseline data included as a covariate. All of the analyses included leukocyte sub-population (e.g. the percentage of granulocytes) as a covariate with the exception of the DNA damage variable which only contains PBMCs. Additional candidates for entry as covariates into the statistical models are listed in <xref ref-type="table" rid="pone-0046736-t001">Table 1</xref>. Covariates and interaction terms that did not achieve a statistical significance of <italic>P</italic>&#x02264;0.05 were removed from the models in a stepwise process.</p><table-wrap id="pone-0046736-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0046736.t001</object-id><label>Table 1</label><caption><title>Baseline (study week 0) characteristics of third trimester pregnant women and nonpregnant women randomized to either the 480 or 930 mg/d choline intake group.</title></caption><alternatives><graphic id="pone-0046736-t001-1" xlink:href="pone.0046736.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Pregnant</td><td colspan="2" align="left" rowspan="1">Nonpregnant</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">480 mg/d (n&#x0200a;=&#x0200a;13)</td><td align="left" rowspan="1" colspan="1">930 mg/d (n&#x0200a;=&#x0200a;13)</td><td align="left" rowspan="1" colspan="1">480 mg/d (n&#x0200a;=&#x0200a;10)</td><td align="left" rowspan="1" colspan="1">930 mg/d (n&#x0200a;=&#x0200a;11)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, y (range)</td><td align="left" rowspan="1" colspan="1">29 (25&#x02013;33)</td><td align="left" rowspan="1" colspan="1">28 (22&#x02013;34)</td><td align="left" rowspan="1" colspan="1">28 (21&#x02013;37)</td><td align="left" rowspan="1" colspan="1">29 (21&#x02013;40)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ethnicity, Caucasian/African American/Latino/Asian/Other</td><td align="left" rowspan="1" colspan="1">9/0/2/1/1</td><td align="left" rowspan="1" colspan="1">7/1/2/3/0</td><td align="left" rowspan="1" colspan="1">8/1/1/0/0</td><td align="left" rowspan="1" colspan="1">6/1/1/1/2</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup> (range)<xref ref-type="table-fn" rid="nt101">a</xref>
</td><td align="left" rowspan="1" colspan="1">23.6 (20.2&#x02013;31.9)</td><td align="left" rowspan="1" colspan="1">23.6 (19.9&#x02013;29.8)</td><td align="left" rowspan="1" colspan="1">23.6 (19.6&#x02013;27.3)</td><td align="left" rowspan="1" colspan="1">23.5 (18.2&#x02013;29.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Education, high school/college</td><td align="left" rowspan="1" colspan="1">1/12</td><td align="left" rowspan="1" colspan="1">3/10</td><td align="left" rowspan="1" colspan="1">3/7</td><td align="left" rowspan="1" colspan="1">3/8</td></tr><tr><td align="left" rowspan="1" colspan="1">Physical activity, usual daily activity/exercise &#x02265;3 times per wk/unknown</td><td align="left" rowspan="1" colspan="1">5/7/1</td><td align="left" rowspan="1" colspan="1">1/10/2</td><td align="left" rowspan="1" colspan="1">2/8/0</td><td align="left" rowspan="1" colspan="1">1/9/1</td></tr><tr><td align="left" rowspan="1" colspan="1">Vitamin supplement consumption, yes/no<xref ref-type="table-fn" rid="nt102">b</xref>
</td><td align="left" rowspan="1" colspan="1">11/2</td><td align="left" rowspan="1" colspan="1">11/2</td><td align="left" rowspan="1" colspan="1">2/8</td><td align="left" rowspan="1" colspan="1">5/6</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label>a</label><p>For pregnant women, this parameter represents pre-pregnancy BMI.</p></fn><fn id="nt102"><label>b</label><p>
<italic>P</italic>&#x0003c;0.01 between pregnant and nonpregnant women, Chi-square test.</p></fn></table-wrap-foot></table-wrap><p>Plots and histograms of the residuals were used to assess normality in the models. Dependent variables that deviated from the normal distribution (e.g. global histone methylation and quantitative PCR data) were logarithmically transformed to meet the assumption of normality. Differences were considered to be significant at <italic>P</italic>&#x02264;0.05; <italic>P</italic>&#x0003c;0.10 was considered to be indicative of trends. Values are presented as means &#x000b1; SEM. If covariates were retained in the final models, the values presented are predicted means; <italic>P</italic> values are two-tailed. All analyses were performed using SPSS (release 18.0 for Windows, SPSS Inc, Chicago, IL).</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Participant characteristics</title><p>The characteristics of the study population at study-baseline (wk-0) are shown in <xref ref-type="table" rid="pone-0046736-t001">Table 1</xref>. Third trimester pregnant and nonpregnant women did not differ in their age, ethnicity/race, pre-pregnancy BMI, education, or physical activity. However, vitamin supplement consumption was greater (<italic>P</italic>&#x0003c;0.01) among pregnant women. No differences (<italic>P</italic>&#x0003e;0.13) in the baseline characteristics were detected among the choline intake groups (<xref ref-type="table" rid="pone-0046736-t001">Table 1</xref>). All pregnant women delivered their babies at term without major complications and their babies were apparently healthy <xref rid="pone.0046736-Yan1" ref-type="bibr">[16]</xref>.</p></sec><sec id="s3b"><title>The effects of choline</title><p>No main effects of choline (P&#x0003e;0.05) were detected for any of the dependent variables. However, choline intake interacted (<italic>P</italic>&#x0200a;=&#x0200a;0.03) with pregnancy status to affect H3K4me2. After stratifying by pregnancy status, H3K4me2 was higher (<italic>P</italic>&#x0200a;=&#x0200a;0.04, controlling for the leukocyte sub-populations) in the 930 versus 480 mg choline/d group among pregnant women (<xref ref-type="fig" rid="pone-0046736-g001">Figure 1</xref>). This relationship did not achieve statistical significance among nonpregnant women (<italic>P</italic>&#x0200a;=&#x0200a;0.12). No additional choline &#x000d7; pregnancy interactions (<italic>P</italic>&#x0003e;0.05) were detected.</p><fig id="pone-0046736-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0046736.g001</object-id><label>Figure 1</label><caption><title>Effect of choline intake on peripheral blood leukocyte H3K4me2.</title><p>The relative abundance of H3K4me2 at study-end in third trimester pregnant women (right) and nonpregnant women (left) consuming 930 versus 480 mg choline/d. White bar: 480 mg choline/d group, black bar: 930 mg choline/d group. n&#x0200a;=&#x0200a;10&#x02013;13/choline intake and pregnancy status. Values are predicted means &#x000b1; SEM. Analyzed with general linear models.</p></caption><graphic xlink:href="pone.0046736.g001"/></fig></sec><sec id="s3c"><title>The effects of pregnancy</title><p>A main effect of pregnancy was detected for several of the dependent variables at study-baseline and study-end (values taken after controlled feeding and choline randomization) as described in subsequent text. The pregnancy effect was not modified by choline intake (i.e., no significant pregnancy &#x000d7; choline interactions were detected for any of the variables) at study-end indicating an effect of pregnancy that is independent of choline intake.</p><sec id="s3c1"><title>Peripheral blood leukocyte counts</title><p>Granulocytes and monocytes are important components of the innate immune system. Third trimester pregnant women exhibited higher (<italic>P</italic>&#x0003c;0.01) granulocyte counts (the majority of which was neutrophils) and borderline higher (<italic>P</italic>&#x0003c;0.09) monocyte counts than nonpregnant women at both study-baseline and study-end. Lymphocyte count was not altered by pregnancy (<xref ref-type="table" rid="pone-0046736-t002">Table 2</xref>).</p><table-wrap id="pone-0046736-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0046736.t002</object-id><label>Table 2</label><caption><title>Peripheral blood leukocyte counts in third trimester pregnant women and nonpregnant women at the beginning and end of the controlled feeding study.</title></caption><alternatives><graphic id="pone-0046736-t002-2" xlink:href="pone.0046736.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">Study-baseline</td><td colspan="3" align="left" rowspan="1">Study-end</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Pregnant</td><td align="left" rowspan="1" colspan="1">Nonpregnant</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value</td><td align="left" rowspan="1" colspan="1">Pregnant</td><td align="left" rowspan="1" colspan="1">Nonpregnant</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;26)</td><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;21)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;26)</td><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;21)</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Leukocytes (&#x000d7;10<sup>3</sup>/&#x000b5;L)</td><td align="left" rowspan="1" colspan="1">9.8&#x000b1;0.5</td><td align="left" rowspan="1" colspan="1">6.1&#x000b1;0.2</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.01</td><td align="left" rowspan="1" colspan="1">9.7&#x000b1;0.5</td><td align="left" rowspan="1" colspan="1">6.3&#x000b1;0.3</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphocytes (&#x000d7;10<sup>3</sup>/&#x000b5;L)</td><td align="left" rowspan="1" colspan="1">1.8&#x000b1;0.1</td><td align="left" rowspan="1" colspan="1">1.9&#x000b1;0.1</td><td align="left" rowspan="1" colspan="1">0.30</td><td align="left" rowspan="1" colspan="1">2.0&#x000b1;0.1</td><td align="left" rowspan="1" colspan="1">2.1&#x000b1;0.1</td><td align="left" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1">Monocytes (&#x000d7;10<sup>3</sup>/&#x000b5;L)</td><td align="left" rowspan="1" colspan="1">0.3&#x000b1;0.03</td><td align="left" rowspan="1" colspan="1">0.2&#x000b1;0.02</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.01</td><td align="left" rowspan="1" colspan="1">0.3&#x000b1;0.02</td><td align="left" rowspan="1" colspan="1">0.2&#x000b1;0.02</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">Granulocytes (&#x000d7;10<sup>3</sup>/&#x000b5;L)</td><td align="left" rowspan="1" colspan="1">7.7&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">4.0&#x000b1;0.2</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.01</td><td align="left" rowspan="1" colspan="1">7.4&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">3.9&#x000b1;0.2</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Granulocyte (%)</td><td align="left" rowspan="1" colspan="1">78.2&#x000b1;0.9</td><td align="left" rowspan="1" colspan="1">65.4&#x000b1;1.4</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.01</td><td align="left" rowspan="1" colspan="1">75.4&#x000b1;0.9</td><td align="left" rowspan="1" colspan="1">62.5&#x000b1;1.6</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.01</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label/><p>Data were analyzed using general linear models.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c2"><title>Leukocyte genome wide expression</title><p>There were 1068 upregulated and 244 downregulated genes at study-baseline, and 1048 upregulated and 280 downregulated genes at study-end, in pregnant versus nonpregnant women (<xref ref-type="fig" rid="pone-0046736-g002">Figure 2</xref>). Of these &#x0223c;1300 differentially expressed genes, 932 were altered at both study-baseline and study-end (<xref ref-type="supplementary-material" rid="pone.0046736.s001">Table S1</xref>). The differential expression of select genes was verified by quantitative PCR (<xref ref-type="table" rid="pone-0046736-t003">Table 3</xref>). Gene expression did not differ between study-end and study-baseline, suggesting that the leukocyte gene expression profile was stable throughout the third trimester of pregnancy.</p><fig id="pone-0046736-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0046736.g002</object-id><label>Figure 2</label><caption><title>Venn diagram of differentially expressed genes by pregnancy.</title><p>This figure presents the number of genes differentially expressed in third trimester pregnant versus nonpregnant women at study-baseline (circle on the left) and study-end (circle on the right). The number of genes altered both at study-baseline and study-end are presented in the intersecting area of the two circles. Color scheme: blue represents low expression and yellow represents high expression. n&#x0200a;=&#x0200a;12 for pregnant women; n&#x0200a;=&#x0200a;10 for nonpregnant women. Analyzed with the LEMMA statistical package.</p></caption><graphic xlink:href="pone.0046736.g002"/></fig><table-wrap id="pone-0046736-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0046736.t003</object-id><label>Table 3</label><caption><title>Quantitative PCR verification of microarray results of genes differentially expressed in third trimester pregnant women (n&#x0200a;=&#x0200a;12) and nonpregnant women (n&#x0200a;=&#x0200a;10) at the end of the controlled feeding study.</title></caption><alternatives><graphic id="pone-0046736-t003-3" xlink:href="pone.0046736.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Gene symbol</td><td align="left" rowspan="1" colspan="1">Gene name</td><td align="left" rowspan="1" colspan="1">Function</td><td colspan="2" align="left" rowspan="1">Total transcript abundance</td><td colspan="2" align="left" rowspan="1">Transcript abundance/percent granulocyte</td><td colspan="2" align="left" rowspan="1">Transcript abundance/granulocyte count</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Fold change</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value</td><td align="left" rowspan="1" colspan="1">Fold change</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value</td><td align="left" rowspan="1" colspan="1">Fold change</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>OLFM4</italic>
</td><td align="left" rowspan="1" colspan="1">Olfactomedin 4</td><td align="left" rowspan="1" colspan="1">Cell adhesion</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>LTF</italic>
</td><td align="left" rowspan="1" colspan="1">Lactoferrin</td><td align="left" rowspan="1" colspan="1">Host defense</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>ELANE</italic>
</td><td align="left" rowspan="1" colspan="1">Elastase</td><td align="left" rowspan="1" colspan="1">Virulence factor degradation</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>DEFA4</italic>
</td><td align="left" rowspan="1" colspan="1">Defensin, alpha 4</td><td align="left" rowspan="1" colspan="1">Host defense</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><label/><p>Data were analyzed with general linear models. Fold change was calculated as the average transcript abundance in pregnant women/the average transcript abundance in nonpregnant women.</p></fn></table-wrap-foot></table-wrap><p>The GO analyses conducted at study-baseline and study-end showed similar biological themes: thus, only the GO results at study-end are presented. At study-end, 246 molecular function categories were altered (<italic>P</italic>&#x0003c;0.01) (<xref ref-type="supplementary-material" rid="pone.0046736.s002">Table S2</xref>), &#x0223c;40% of which was related to immune response. The GO of defense response (GO: 0006952) showed the most significant alteration. Of the 112 defense response genes altered, 105 were upregulated in third trimester pregnant women as compared to nonpregnant women (<xref ref-type="fig" rid="pone-0046736-g003">Figure 3</xref>). To evaluate whether the elevated expression of defense response genes was mediated at least in part by the activation of granulocytes, we used leukocyte sub-population as a covariate in the statistical models. After adjusting for leukocyte sub-populations, the greater expression of the defense response genes among pregnant women was maintained (examples are shown in <xref ref-type="table" rid="pone-0046736-t003">Table 3</xref> and <xref ref-type="table" rid="pone-0046736-t004">4</xref>), suggesting that the higher expression of defense response genes was not solely a function of higher granulocyte counts, but also due to enhanced activation of the granulocytes.</p><fig id="pone-0046736-g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0046736.g003</object-id><label>Figure 3</label><caption><title>Hierarchical clustering of differentially expressed immune defense genes (GO: 0006952) in pregnant versus nonpregnant women.</title><p>This figure presents the hierarchical clustering of 112 differentially expressed immune defense genes in third trimester women versus nonpregnant women (reference group) at the beginning and end of the controlled feeding study. Color scheme: blue represents low expression and yellow represents high expression. n&#x0200a;=&#x0200a;12 for pregnant women; n&#x0200a;=&#x0200a;10 for nonpregnant women. Analyzed with Euclidean distances using MultiExperiment Viewer.</p></caption><graphic xlink:href="pone.0046736.g003"/></fig><table-wrap id="pone-0046736-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0046736.t004</object-id><label>Table 4</label><caption><title>Select list of genes involved in defense response that were upregulated in third trimester pregnant women at the end of the controlled feeding study.</title></caption><alternatives><graphic id="pone-0046736-t004-4" xlink:href="pone.0046736.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Gene symbol</td><td align="left" rowspan="1" colspan="1">Gene name</td><td align="left" rowspan="1" colspan="1">Category</td><td align="left" rowspan="1" colspan="1">Fold change (unadjusted)</td><td align="left" rowspan="1" colspan="1">Fold change (adjusted)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>CD14</italic>
</td><td align="left" rowspan="1" colspan="1">CD14 molecule</td><td align="left" rowspan="1" colspan="1">Surface marker</td><td align="left" rowspan="1" colspan="1">2.30</td><td align="left" rowspan="1" colspan="1">1.77</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>TLR1</italic>
</td><td align="left" rowspan="1" colspan="1">Toll-like receptor 1</td><td align="left" rowspan="1" colspan="1">TLR signaling pathway</td><td align="left" rowspan="1" colspan="1">2.16</td><td align="left" rowspan="1" colspan="1">1.79</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>TLR4</italic>
</td><td align="left" rowspan="1" colspan="1">Toll-like receptor 4</td><td align="left" rowspan="1" colspan="1">TLR signaling pathway</td><td align="left" rowspan="1" colspan="1">2.47</td><td align="left" rowspan="1" colspan="1">1.94</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>TLR5</italic>
</td><td align="left" rowspan="1" colspan="1">Toll-like receptor 5</td><td align="left" rowspan="1" colspan="1">TLR signaling pathway</td><td align="left" rowspan="1" colspan="1">3.07</td><td align="left" rowspan="1" colspan="1">2.43</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>TLR6</italic>
</td><td align="left" rowspan="1" colspan="1">Toll-like receptor 6</td><td align="left" rowspan="1" colspan="1">TLR signaling pathway</td><td align="left" rowspan="1" colspan="1">2.51</td><td align="left" rowspan="1" colspan="1">1.97</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>MYD88</italic>
</td><td align="left" rowspan="1" colspan="1">Myeloid differentiation primary response gene (88)</td><td align="left" rowspan="1" colspan="1">TLR signaling pathway</td><td align="left" rowspan="1" colspan="1">2.02</td><td align="left" rowspan="1" colspan="1">1.51</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>ELANE</italic>
</td><td align="left" rowspan="1" colspan="1">Elastase, neutrophil expressed</td><td align="left" rowspan="1" colspan="1">Azurophil granule protein</td><td align="left" rowspan="1" colspan="1">11.05</td><td align="left" rowspan="1" colspan="1">13.77</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>MPO</italic>
</td><td align="left" rowspan="1" colspan="1">Myeloperoxidase</td><td align="left" rowspan="1" colspan="1">Azurophil granule protein</td><td align="left" rowspan="1" colspan="1">7.25</td><td align="left" rowspan="1" colspan="1">7.44</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>AZU1</italic>
</td><td align="left" rowspan="1" colspan="1">Azurocidin 1</td><td align="left" rowspan="1" colspan="1">Azurophil granule protein</td><td align="left" rowspan="1" colspan="1">2.94</td><td align="left" rowspan="1" colspan="1">2.93</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CTSG</italic>
</td><td align="left" rowspan="1" colspan="1">Cathepsin G</td><td align="left" rowspan="1" colspan="1">Azurophil granule protein</td><td align="left" rowspan="1" colspan="1">7.50</td><td align="left" rowspan="1" colspan="1">7.03</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>DEFA1</italic>
</td><td align="left" rowspan="1" colspan="1">Defensin, alpha 1</td><td align="left" rowspan="1" colspan="1">Azurophil granule protein</td><td align="left" rowspan="1" colspan="1">4.76</td><td align="left" rowspan="1" colspan="1">3.72</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>DEFA3</italic>
</td><td align="left" rowspan="1" colspan="1">Defensin, alpha 3, neutrophil-specific</td><td align="left" rowspan="1" colspan="1">Azurophil granule protein</td><td align="left" rowspan="1" colspan="1">7.53</td><td align="left" rowspan="1" colspan="1">4.97</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>DEFA4</italic>
</td><td align="left" rowspan="1" colspan="1">Defensin, alpha 4, corticostatin</td><td align="left" rowspan="1" colspan="1">Azurophil granule protein</td><td align="left" rowspan="1" colspan="1">26.95</td><td align="left" rowspan="1" colspan="1">25.81</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>LTF</italic>
</td><td align="left" rowspan="1" colspan="1">Lactotransferrin</td><td align="left" rowspan="1" colspan="1">Specific granule protein</td><td align="left" rowspan="1" colspan="1">35.51</td><td align="left" rowspan="1" colspan="1">26.33</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CAMP</italic>
</td><td align="left" rowspan="1" colspan="1">Cathelicidin antimicrobial peptide</td><td align="left" rowspan="1" colspan="1">Specific granule protein</td><td align="left" rowspan="1" colspan="1">17.48</td><td align="left" rowspan="1" colspan="1">15.59</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>C1QB</italic>
</td><td align="left" rowspan="1" colspan="1">Complement component 1, q subcomponent, B</td><td align="left" rowspan="1" colspan="1">Complement system</td><td align="left" rowspan="1" colspan="1">3.35</td><td align="left" rowspan="1" colspan="1">2.62</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CR1</italic>
</td><td align="left" rowspan="1" colspan="1">Complement component (3 b/4 b) receptor 1</td><td align="left" rowspan="1" colspan="1">Complement system</td><td align="left" rowspan="1" colspan="1">3.20</td><td align="left" rowspan="1" colspan="1">2.50</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>C2</italic>
</td><td align="left" rowspan="1" colspan="1">Complement component 2</td><td align="left" rowspan="1" colspan="1">Complement system</td><td align="left" rowspan="1" colspan="1">3.58</td><td align="left" rowspan="1" colspan="1">2.80</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>IL1B</italic>
</td><td align="left" rowspan="1" colspan="1">Interleukin 1, beta</td><td align="left" rowspan="1" colspan="1">Cytokine signaling</td><td align="left" rowspan="1" colspan="1">2.78</td><td align="left" rowspan="1" colspan="1">2.14</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>IL1R1</italic>
</td><td align="left" rowspan="1" colspan="1">Interleukin 1 receptor, type I</td><td align="left" rowspan="1" colspan="1">Cytokine signaling</td><td align="left" rowspan="1" colspan="1">2.42</td><td align="left" rowspan="1" colspan="1">1.77</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>IL8RB</italic>
</td><td align="left" rowspan="1" colspan="1">Interleukin 8 receptor, beta</td><td align="left" rowspan="1" colspan="1">Cytokine signaling</td><td align="left" rowspan="1" colspan="1">2.86</td><td align="left" rowspan="1" colspan="1">2.23</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>IL8RA</italic>
</td><td align="left" rowspan="1" colspan="1">Interleukin 8 receptor, alpha</td><td align="left" rowspan="1" colspan="1">Cytokine signaling</td><td align="left" rowspan="1" colspan="1">2.81</td><td align="left" rowspan="1" colspan="1">2.19</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt105"><label/><p>
<italic>P</italic> values&#x0003c;0.05 with or without adjusting for leukocyte sub-populations as analyzed with general linear models or the LEMMA statistical package, respectively. Fold change was calculated as the average transcript abundance in pregnant women/the average transcript abundance in nonpregnant women.</p></fn></table-wrap-foot></table-wrap><p>Among pregnant women, several components of the toll-like receptor (TLR) signaling pathway were upregulated, including the genes encoding TLR1, 4, 5, 6; the CD molecule 14 (<italic>CD14</italic>), a major surface marker of neutrophils and monocytes that interacts with TLR4; and myeloid differentiation primary response gene 88 (<italic>MYD88</italic>). The TLRs are pattern recognition molecules on immune cells (e.g., neutrophils) that recognize pathogenic elements (e.g., lipopolysaccharides) and illicit a signaling cascade involving MYD88 that results in the increased production of proinflammatory cytokines such as interleukin 1&#x003b2; (IL1&#x003b2;) and the chemokine interleukin 8 (IL8) <xref rid="pone.0046736-Drewniak1" ref-type="bibr">[28]</xref>, <xref rid="pone.0046736-Grishman1" ref-type="bibr">[29]</xref>. The increased IL8 production favors chemotaxis and survival of the neutrophils <xref rid="pone.0046736-Mantovani1" ref-type="bibr">[30]</xref>.</p><p>Third trimester pregnant women also exhibited higher expression of genes encoding: (i) the microbicidal proteins stored in the neutrophil granules [e.g. the azurophil proteins elastase (<italic>ELANE</italic>), alpha-defensins (<italic>DEFA</italic>) and specific granule proteins lactoferrin (<italic>LTF</italic>) and catheticidin (<italic>CAMP</italic>)]; (ii) the complement proteins involved in innate humoral immune response [e.g. complement component 1, q subcomponent, B chain (<italic>C1QB</italic>), complement component 2 (<italic>C2</italic>) and complement component (3 b/4 b) receptor 1 (<italic>CR1</italic>)]; (iii) proteins involved in neutrophil superoxide anion production [e.g. the NADPH oxidase complex neutrophil cytosolic factors (<italic>NCF</italic>), and myeloperoxidase (<italic>MPO</italic>)]; and (iv) the proinflammatory cytokines (e.g. <italic>IL1B</italic>). The GO of TNF (GO:0032640) and IL6 (GO:0032675) production were also upregulated.</p><p>Only a few (&#x0223c;8) immune response genes were downregulated among pregnant women after controlling for the leukocyte sub-populations. The repressed genes were mostly associated with the adaptive immune response (<xref ref-type="table" rid="pone-0046736-t005">Table 5</xref>) and included: (i) the transmembrane glycoprotein CD1 family members CD1c and CD1e molecules, which present primary lipid and glycolipid antigens to T cells <xref rid="pone.0046736-Dascher1" ref-type="bibr">[31]</xref>; (ii) the chemokine (C-C motif) receptors <italic>CCR6</italic> and <italic>CCR9</italic>, which are preferably expressed by T cells <xref rid="pone.0046736-Oldham1" ref-type="bibr">[32]</xref>, <xref rid="pone.0046736-Stenstad1" ref-type="bibr">[33]</xref>; (iii) CD70 molecule, a surface antigen on activated T and B lymphocytes <xref rid="pone.0046736-Denoeud1" ref-type="bibr">[34]</xref> and (iv) B-cell linker protein (<italic>BLNK</italic>), which plays an important role in B cell development and receptor signaling <xref rid="pone.0046736-Koretzky1" ref-type="bibr">[35]</xref>.</p><table-wrap id="pone-0046736-t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0046736.t005</object-id><label>Table 5</label><caption><title>Genes involved in adaptive immune response that were downregulated in third trimester pregnant women at the end of the controlled feeding study.</title></caption><alternatives><graphic id="pone-0046736-t005-5" xlink:href="pone.0046736.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Gene symbol</td><td align="left" rowspan="1" colspan="1">Gene name</td><td align="left" rowspan="1" colspan="1">Function</td><td align="left" rowspan="1" colspan="1">Fold change (unadjusted)</td><td align="left" rowspan="1" colspan="1">Fold change (adjusted)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>CD70</italic>
</td><td align="left" rowspan="1" colspan="1">CD70 molecule</td><td align="left" rowspan="1" colspan="1">Activated T and B cell marker</td><td align="left" rowspan="1" colspan="1">0.47</td><td align="left" rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CD1C</italic>
</td><td align="left" rowspan="1" colspan="1">CD1c molecule</td><td align="left" rowspan="1" colspan="1">Antigen presentation</td><td align="left" rowspan="1" colspan="1">0.46</td><td align="left" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CD1E</italic>
</td><td align="left" rowspan="1" colspan="1">CD1e molecule</td><td align="left" rowspan="1" colspan="1">Antigen presentation</td><td align="left" rowspan="1" colspan="1">0.42</td><td align="left" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CCR6</italic>
</td><td align="left" rowspan="1" colspan="1">chemokine (C-C motif) receptor 6</td><td align="left" rowspan="1" colspan="1">T cell recruitment</td><td align="left" rowspan="1" colspan="1">0.34</td><td align="left" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CCR9</italic>
</td><td align="left" rowspan="1" colspan="1">chemokine (C-C motif) receptor 9</td><td align="left" rowspan="1" colspan="1">T cell recruitment</td><td align="left" rowspan="1" colspan="1">0.50</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>BLNK</italic>
</td><td align="left" rowspan="1" colspan="1">B cell linker</td><td align="left" rowspan="1" colspan="1">B cell receptor signaling</td><td align="left" rowspan="1" colspan="1">0.38</td><td align="left" rowspan="1" colspan="1">0.47</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt106"><label/><p>
<italic>P</italic> values&#x0003c;0.05 with or without adjusting for leukocyte sub-populations as analyzed with general linear models or the LEMMA statistical package, respectively. Fold change was calculated as the average transcript abundance in pregnant women/the average transcript abundance in nonpregnant women.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c3"><title>Plasma TNF&#x003b1;and IL6</title><p>Circulating concentrations of TNF&#x003b1; were higher among pregnant women at study-end (1.18&#x000b1;0.09 vs. 0.94&#x000b1;0.07 pg/mL, <italic>P</italic>&#x0200a;=&#x0200a;0.05) but not at study-baseline (1.19&#x000b1;0.16 vs. 0.94&#x000b1;0.09 pg/mL, <italic>P</italic>&#x0200a;=&#x0200a;0.19). IL6 was elevated among pregnant women at both study-baseline (1.22&#x000b1;0.19 vs. 0.73&#x000b1;0.07 pg/mL, <italic>P</italic>&#x0200a;=&#x0200a;0.02) and study-end (1.50&#x000b1;0.15 vs. 0.73&#x000b1;0.10 pg/mL, <italic>P</italic>&#x0003c;0.01) (<xref ref-type="fig" rid="pone-0046736-g004">Figure 4</xref>). The higher circulating concentrations of TNF&#x003b1; and IL6 among pregnant women at study-end corresponded with the microarray GO results showing upregulation of TNF and IL6 production.</p><fig id="pone-0046736-g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0046736.g004</object-id><label>Figure 4</label><caption><title>Plasma TNF&#x003b1; and IL6 concentrations.</title><p>Plasma concentrations of TNF&#x003b1; and IL6 in third trimester pregnant versus nonpregnant women at study-baseline (<bold>A</bold>) and study-end (<bold>B</bold>). White bar: nonpregnant women (n&#x0200a;=&#x0200a;21); black bar: pregnant women (n&#x0200a;=&#x0200a;26). Values are means &#x000b1; SEM. Analyzed with general linear models.</p></caption><graphic xlink:href="pone.0046736.g004"/></fig></sec><sec id="s3c4"><title>Leukocyte percent tail DNA</title><p>Third trimester pregnant women had significantly higher (<italic>P</italic>&#x0003c;0.01) percent tail DNA than nonpregnant women at study-baseline and study-end (<xref ref-type="table" rid="pone-0046736-t006">Table 6</xref>). The higher percent tail DNA represents greater DNA strand breakage due to oxidative stress.</p><table-wrap id="pone-0046736-t006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0046736.t006</object-id><label>Table 6</label><caption><title>Leukocyte DNA damage and global DNA methylation in third trimester pregnant women and nonpregnant women consuming 480 or 930 mg choline/d at the beginning and end of the controlled feeding study.</title></caption><alternatives><graphic id="pone-0046736-t006-6" xlink:href="pone.0046736.t006"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">Pregnant</td><td colspan="3" align="left" rowspan="1">Nonpregnant</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">480 mg/d</td><td align="left" rowspan="1" colspan="1">930 mg/d</td><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">480 mg/d</td><td align="left" rowspan="1" colspan="1">930 mg/d</td><td align="left" rowspan="1" colspan="1">Total</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;13)</td><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;13)</td><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;26)</td><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;10)</td><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;11)</td><td align="left" rowspan="1" colspan="1">(n&#x0200a;=&#x0200a;21)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Percent tail DNA</italic></bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Study-beginning</td><td align="left" rowspan="1" colspan="1">44.9&#x000b1;3.6</td><td align="left" rowspan="1" colspan="1">43.5&#x000b1;4.8</td><td align="left" rowspan="1" colspan="1">44.3&#x000b1;2.9<xref ref-type="table-fn" rid="nt108">*</xref>
</td><td align="left" rowspan="1" colspan="1">26.4&#x000b1;2.9</td><td align="left" rowspan="1" colspan="1">27.8&#x000b1;4.0</td><td align="left" rowspan="1" colspan="1">27.1&#x000b1;2.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Study-end</td><td align="left" rowspan="1" colspan="1">33.2&#x000b1;4.6</td><td align="left" rowspan="1" colspan="1">43.5&#x000b1;4.8</td><td align="left" rowspan="1" colspan="1">38.3&#x000b1;3.4<xref ref-type="table-fn" rid="nt108">*</xref>
</td><td align="left" rowspan="1" colspan="1">20.6&#x000b1;1.9</td><td align="left" rowspan="1" colspan="1">24.9&#x000b1;1.5</td><td align="left" rowspan="1" colspan="1">22.9&#x000b1;1.6</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>DNA methylation</italic></bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Study-beginning</td><td align="left" rowspan="1" colspan="1">5.1&#x000b1;0.2</td><td align="left" rowspan="1" colspan="1">5.2&#x000b1;0.2</td><td align="left" rowspan="1" colspan="1">5.1&#x000b1;0.1</td><td align="left" rowspan="1" colspan="1">4.9&#x000b1;0.2</td><td align="left" rowspan="1" colspan="1">5.2&#x000b1;0.2</td><td align="left" rowspan="1" colspan="1">5.1&#x000b1;0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Study-end</td><td align="left" rowspan="1" colspan="1">5.2&#x000b1;0.2</td><td align="left" rowspan="1" colspan="1">5.1&#x000b1;0.2</td><td align="left" rowspan="1" colspan="1">5.1&#x000b1;0.1</td><td align="left" rowspan="1" colspan="1">5.0&#x000b1;0.1</td><td align="left" rowspan="1" colspan="1">4.8&#x000b1;0.2</td><td align="left" rowspan="1" colspan="1">4.9&#x000b1;0.1</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt107"><label/><p>Data were analyzed with general linear models.</p></fn><fn id="nt108"><label>*</label><p>
<italic>P</italic>&#x0003c;0.01 between pregnant and nonpregnant women.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c5"><title>Leukocyte global histone and DNA methylation</title><p>Third trimester pregnant women (versus nonpregnant women) had lower levels of the transcription activation histone mark H3K4me2 (<italic>P</italic>&#x0003c;0.01), and the transcription repression mark H3K9me2 (<italic>P</italic>&#x0200a;=&#x0200a;0.05) at study-baseline and study-end (not controlling for leukocyte sub-populations) (<xref ref-type="fig" rid="pone-0046736-g005">Figure 5, A and C</xref>). However, after controlling for leukocyte sub-populations, the effect of pregnancy disappeared (<xref ref-type="fig" rid="pone-0046736-g005">Figure 5, B and D</xref>), suggesting that the alterations in leukocyte H3K9me2 and H3K4me2 during pregnancy were a function of the shift in the leukocyte sub-populations and that different leukocyte cell types may have a different abundance of these histone modifications. Global DNA methylation (study-baseline or study-end) was not altered (P&#x0003e;0.38) by pregnancy (<xref ref-type="table" rid="pone-0046736-t006">Table 6</xref>).</p><fig id="pone-0046736-g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0046736.g005</object-id><label>Figure 5</label><caption><title>Peripheral blood leukocyte histone modification marks H3K4me2, H3K9me2 and H3K27me3.</title><p>(<bold>A</bold>) and (<bold>C</bold>), histone modifications in third trimester pregnant versus nonpregnant women without controlling for percent granulocytes at study-baseline and study-end, respectively; (<bold>B</bold>) and (<bold>D</bold>), histone modifications in third trimester pregnant versus nonpregnant women controlling for percent granulocytes at study-baseline or study-end, respectively. White bar: nonpregnant women (n&#x0200a;=&#x0200a;21), black bar: pregnant women (n&#x0200a;=&#x0200a;26). Data are predicted means &#x000b1; SEM. Analyzed with general linear models.</p></caption><graphic xlink:href="pone.0046736.g005"/></fig></sec></sec></sec><sec id="s4"><title>Discussion</title><p>Genomic markers were investigated among healthy third trimester pregnant and nonpregnant control women to advance our understanding of pregnancy induced alterations in immune response, redox balance, and epigenomic stability. The effect of maternal choline intake on these genomic markers was also investigated secondary to the role of choline as a methyl donor. Under both uncontrolled (study-baseline) and controlled (study-end) dietary conditions, our data demonstrate that healthy third trimester pregnant women experience transcriptional activation of the peripheral innate immune system and elevated oxidative stress as indicated by higher DNA damage. Our data also indicate that a choline intake exceeding current dietary recommendations does not alter blood leukocyte genomic markers, except for H3K4me2 among third-trimester pregnant women.</p><sec id="s4a"><title>The effects of pregnancy</title><sec id="s4a1"><title>Immune Function</title><p>Pregnant women experienced an elevation in the transcript abundance of 105 leukocyte defense response genes as compared to nonpregnant control women. The majority of upregulated defense genes were neutrophil-associated genes including neutrophil surface markers (e.g. <italic>CD14</italic>), pattern recognition molecules, cytokines, chemokines, neutrophil granule proteins, complement proteins and neutrophil oxidases. Importantly, the greater transcription of these host defense genes among third trimester pregnant women persisted after controlling for the leukocyte sub-populations, indicating transcriptional activation, rather than suppression, of individual neutrophils. The activation of peripheral neutrophils (and the innate immune system) during the last third of human pregnancy may serve as a compensatory mechanism to protect the maternal-fetal dyad against pathogens when the adaptive immune response is suppressed. Overall our data provide a blueprint of pregnancy induced changes in the peripheral blood transcriptome and elucidate new pathways and molecules that function in the modulation of the immune system during the third trimester of human pregnancy.</p></sec><sec id="s4a2"><title>Oxidative stress and DNA damage</title><p>Leukocyte DNA damage was approximately two times greater among third trimester pregnant women than nonpregnant control women. This elevation in DNA damage among pregnant women may arise from increases in oxidative stress particularly as pregnancy advances <xref rid="pone.0046736-Furness1" ref-type="bibr">[9]</xref>. Healthy pregnant women were previously thought to overcome oxidative stress through upregulation of antioxidation machinery <xref rid="pone.0046736-Qanungo1" ref-type="bibr">[36]</xref>, <xref rid="pone.0046736-Wang1" ref-type="bibr">[37]</xref>. However, our study suggests that DNA damage commonly occurs throughout the last third of uncomplicated pregnancies.</p><p>It is noteworthy that oxidative stress and immune activation are interrelated. Neutrophils are both activated by, and a producer of, reactive oxygen species. TLR4 signaling is enhanced by reactive oxygen species, leading to sustained production of proinflammatory proteins, which in turn maintain oxidative stress <xref rid="pone.0046736-Vidali1" ref-type="bibr">[38]</xref>. In addition, activated neutrophils are a significant source of reactive oxygen species via the activity of NADPH oxidase and myeloperoxidase (MPO) <xref rid="pone.0046736-Lamb1" ref-type="bibr">[39]</xref>, which were both upregulated among pregnant women in our study. Although the increased oxidative stress appears to be a normal event of pregnancy, the DNA damage by reactive oxygen species can lead to genomic instability, aberrant gene expression and apoptosis <xref rid="pone.0046736-Cooke1" ref-type="bibr">[40]</xref>, <xref rid="pone.0046736-Collins1" ref-type="bibr">[41]</xref>. Additional studies are needed to address the health effects of pregnancy-induced leukocyte DNA damage and whether the DNA damage resolves after delivery.</p></sec></sec><sec id="s4b"><title>The effects of choline intake</title><p>A higher maternal choline intake during pregnancy increased dimethylation of H3K4, which is indicative of active transcription <xref rid="pone.0046736-Kim1" ref-type="bibr">[42]</xref>. To the best of our knowledge, this is the first report in humans that choline intake affected an epigenetic mark of histones obtained from leukocytes of pregnant women. Nevertheless, we did not observe a corresponding change in leukocyte gene expression by choline intake within the time frame of this study and no other genomic marks were affected by maternal choline intake. Thus, unlike the genomic marks (e.g., DNA methylation <xref rid="pone.0046736-Jiang1" ref-type="bibr">[15]</xref> and transcriptome profiles (unpublished data) of developing fetal-derived tissues (i.e., placenta and cord blood leukocytes) which are highly responsive to maternal choline intake, genomic markers of maternal-derived tissue may be relatively unresponsive to changes in maternal choline intake.</p></sec><sec id="s4c"><title>Limitations</title><p>Our study has two major limitations. First, data collection was limited to the third trimester of pregnancy; thus, additional studies are needed to address the effects of pregnancy and maternal choline intake on maternal genomic marks in earlier stages of gestation as well as in the postnatal period. Second, genomic marks from peripheral blood sampling do not necessarily reflect genomic marks in other tissues. Nonetheless, blood transcript profiling is considered a robust tool for assessing the status of the human immune system <xref rid="pone.0046736-Chaussabel1" ref-type="bibr">[43]</xref>, <xref rid="pone.0046736-Pascual1" ref-type="bibr">[44]</xref>, <xref rid="pone.0046736-Talwar1" ref-type="bibr">[45]</xref>.</p></sec><sec id="s4d"><title>Conclusions</title><p>In summary, the last third of human pregnancy is characterized by transcriptional activation of the neutrophils and elevations in maternal leukocyte oxidative DNA damage. These findings are consistent with an upregulation of the peripheral innate immune system which plays a central role in protecting the maternal and fetal dyad against pathogens. Additional studies are needed to delineate the long-term functional consequences of these genomic alterations and to investigate the relationship between these genomic marks and complicated pregnancy.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0046736.s001"><label>Table S1</label><caption><p>
<bold>Genes differentially expressed in third trimester pregnant women and non-pregnant women at week 0 (baseline) and week 12 (study end) of the controlled feeding study.</bold> Benjamini-Hochberg adjusted <italic>P</italic> values&#x0003c;0.05; Data were analyzed with the LEMMA statistical package.</p><p>(XLSX)</p></caption><media xlink:href="pone.0046736.s001.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0046736.s002"><label>Table S2</label><caption><p>
<bold>Gene ontology altered in third trimester pregnant women and non-pregnant women at week 12 (study end) of the controlled feeding study.</bold> Data were analyzed with Gominer.</p><p>(XLSX)</p></caption><media xlink:href="pone.0046736.s002.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0046736-Wegmann1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Wegmann</surname><given-names>TG</given-names></name>, <name><surname>Lin</surname><given-names>H</given-names></name>, <name><surname>Guilbert</surname><given-names>L</given-names></name>, <name><surname>Mosmann</surname><given-names>TR</given-names></name> (<year>1993</year>) <article-title>Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?</article-title>
<source>Immunol Today</source>
<volume>14</volume>: <fpage>353</fpage>&#x02013;<lpage>356</lpage>.<pub-id pub-id-type="pmid">8363725</pub-id></mixed-citation></ref><ref id="pone.0046736-Witkin1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Witkin</surname><given-names>SS</given-names></name>, <name><surname>Linhares</surname><given-names>IM</given-names></name>, <name><surname>Bongiovanni</surname><given-names>AM</given-names></name>, <name><surname>Herway</surname><given-names>C</given-names></name>, <name><surname>Skupski</surname><given-names>D</given-names></name> (<year>2011</year>) <article-title>Unique alterations in infection-induced immune activation during pregnancy</article-title>. <source>BJOG</source>
<volume>118</volume>: <fpage>145</fpage>&#x02013;<lpage>153</lpage>.<pub-id pub-id-type="pmid">21054766</pub-id></mixed-citation></ref><ref id="pone.0046736-Belo1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Belo</surname><given-names>L</given-names></name>, <name><surname>Santos-Silva</surname><given-names>A</given-names></name>, <name><surname>Rocha</surname><given-names>S</given-names></name>, <name><surname>Caslake</surname><given-names>M</given-names></name>, <name><surname>Cooney</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Fluctuations in C-reactive protein concentration and neutrophil activation during normal human pregnancy</article-title>. <source>Eur J Obstet Gynecol Reprod Biol</source>
<volume>123</volume>: <fpage>46</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">16260340</pub-id></mixed-citation></ref><ref id="pone.0046736-Crocker1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Crocker</surname><given-names>I</given-names></name>, <name><surname>Lawson</surname><given-names>N</given-names></name>, <name><surname>Daniels</surname><given-names>I</given-names></name>, <name><surname>Baker</surname><given-names>P</given-names></name>, <name><surname>Fletcher</surname><given-names>J</given-names></name> (<year>1999</year>) <article-title>Significance of fatty acids in pregnancy-induced immunosuppression</article-title>. <source>Clinical and Diagnostic Laboratory Immunology</source>
<volume>6</volume>: <fpage>587</fpage>&#x02013;<lpage>593</lpage>.<pub-id pub-id-type="pmid">10391868</pub-id></mixed-citation></ref><ref id="pone.0046736-Crouch1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Crouch</surname><given-names>SP</given-names></name>, <name><surname>Crocker</surname><given-names>IP</given-names></name>, <name><surname>Fletcher</surname><given-names>J</given-names></name> (<year>1995</year>) <article-title>The effect of pregnancy on polymorphonuclear leukocyte function</article-title>. <source>J Immunol</source>
<volume>155</volume>: <fpage>5436</fpage>&#x02013;<lpage>5443</lpage>.<pub-id pub-id-type="pmid">7594561</pub-id></mixed-citation></ref><ref id="pone.0046736-Luppi1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Luppi</surname><given-names>P</given-names></name>, <name><surname>Haluszczak</surname><given-names>C</given-names></name>, <name><surname>Trucco</surname><given-names>M</given-names></name>, <name><surname>Deloia</surname><given-names>JA</given-names></name> (<year>2002</year>) <article-title>Normal pregnancy is associated with peripheral leukocyte activation</article-title>. <source>Am J Reprod Immunol</source>
<volume>47</volume>: <fpage>72</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">11900591</pub-id></mixed-citation></ref><ref id="pone.0046736-Sacks1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Sacks</surname><given-names>GP</given-names></name>, <name><surname>Studena</surname><given-names>K</given-names></name>, <name><surname>Sargent</surname><given-names>K</given-names></name>, <name><surname>Redman</surname><given-names>CW</given-names></name> (<year>1998</year>) <article-title>Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis</article-title>. <source>Am J Obstet Gynecol</source>
<volume>179</volume>: <fpage>80</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">9704769</pub-id></mixed-citation></ref><ref id="pone.0046736-Casanueva1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Casanueva</surname><given-names>E</given-names></name>, <name><surname>Viteri</surname><given-names>FE</given-names></name> (<year>2003</year>) <article-title>Iron and oxidative stress in pregnancy</article-title>. <source>J Nutr</source>
<volume>133</volume>: <fpage>1700S</fpage>&#x02013;<lpage>1708S</lpage>.<pub-id pub-id-type="pmid">12730487</pub-id></mixed-citation></ref><ref id="pone.0046736-Furness1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Furness</surname><given-names>DL</given-names></name>, <name><surname>Dekker</surname><given-names>GA</given-names></name>, <name><surname>Roberts</surname><given-names>CT</given-names></name> (<year>2011</year>) <article-title>DNA damage and health in pregnancy</article-title>. <source>J Reprod Immunol</source>
<volume>89</volume>: <fpage>153</fpage>&#x02013;<lpage>162</lpage>.<pub-id pub-id-type="pmid">21511343</pub-id></mixed-citation></ref><ref id="pone.0046736-Harma1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Harma</surname><given-names>M</given-names></name>, <name><surname>Kocyigit</surname><given-names>A</given-names></name>, <name><surname>Erel</surname><given-names>O</given-names></name> (<year>2005</year>) <article-title>Increased DNA damage in patients with complete hydatidiform mole</article-title>. <source>Mutat Res</source>
<volume>583</volume>: <fpage>49</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">15866465</pub-id></mixed-citation></ref><ref id="pone.0046736-Zeisel1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Zeisel</surname><given-names>SH</given-names></name> (<year>2009</year>) <article-title>Importance of methyl donors during reproduction</article-title>. <source>Am J Clin Nutr</source>
<volume>89</volume>: <fpage>673S</fpage>&#x02013;<lpage>677S</lpage>.<pub-id pub-id-type="pmid">19116320</pub-id></mixed-citation></ref><ref id="pone.0046736-Kass1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Kass</surname><given-names>SU</given-names></name>, <name><surname>Pruss</surname><given-names>D</given-names></name>, <name><surname>Wolffe</surname><given-names>AP</given-names></name> (<year>1997</year>) <article-title>How does DNA methylation repress transcription?</article-title>
<source>Trends in Genetics</source>
<volume>13</volume>: <fpage>444</fpage>&#x02013;<lpage>449</lpage>.<pub-id pub-id-type="pmid">9385841</pub-id></mixed-citation></ref><ref id="pone.0046736-Cheung1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Cheung</surname><given-names>P</given-names></name>, <name><surname>Lau</surname><given-names>P</given-names></name> (<year>2005</year>) <article-title>Epigenetic regulation by histone methylation and histone variants</article-title>. <source>Molecular Endocrinology</source>
<volume>19</volume>: <fpage>563</fpage>&#x02013;<lpage>573</lpage>.<pub-id pub-id-type="pmid">15677708</pub-id></mixed-citation></ref><ref id="pone.0046736-Institute1"><label>14</label><mixed-citation publication-type="other">Institute of Medicine (1998) Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin and choline. Washington, DC: National Academy Press: 390&#x02013;422.</mixed-citation></ref><ref id="pone.0046736-Jiang1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Jiang</surname><given-names>X</given-names></name>, <name><surname>Yan</surname><given-names>J</given-names></name>, <name><surname>West</surname><given-names>AA</given-names></name>, <name><surname>Perry</surname><given-names>CA</given-names></name>, <name><surname>Malysheva</surname><given-names>OV</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Maternal choline intake alters the epigenetic state of fetal cortisol-regulating genes in humans</article-title>. <source>FASEB J</source>
</mixed-citation></ref><ref id="pone.0046736-Yan1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Yan</surname><given-names>J</given-names></name>, <name><surname>Jiang</surname><given-names>X</given-names></name>, <name><surname>West</surname><given-names>AA</given-names></name>, <name><surname>Perry</surname><given-names>CA</given-names></name>, <name><surname>Malysheva</surname><given-names>OV</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Maternal choline intake modulates maternal and fetal biomarkers of choline metabolism in humans</article-title>. <source>American Journal of Clinical Nutrition</source>
<volume>95</volume>: <fpage>1060</fpage>&#x02013;<lpage>1071</lpage>.<pub-id pub-id-type="pmid">22418088</pub-id></mixed-citation></ref><ref id="pone.0046736-Shin1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Shin</surname><given-names>W</given-names></name>, <name><surname>Yan</surname><given-names>J</given-names></name>, <name><surname>Abratte</surname><given-names>CM</given-names></name>, <name><surname>Vermeylen</surname><given-names>F</given-names></name>, <name><surname>Caudill</surname><given-names>MA</given-names></name> (<year>2010</year>) <article-title>Choline intake exceeding current dietary recommendations preserves markers of cellular methylation in a genetic subgroup of folate-compromised men</article-title>. <source>Journal of Nutrition</source>
<volume>140</volume>: <fpage>975</fpage>&#x02013;<lpage>980</lpage>.<pub-id pub-id-type="pmid">20220206</pub-id></mixed-citation></ref><ref id="pone.0046736-R1"><label>18</label><mixed-citation publication-type="other">R Development Core Team (2011) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing.</mixed-citation></ref><ref id="pone.0046736-Bar1"><label>19</label><mixed-citation publication-type="other">Bar H, Schifano E (2010) Lemma: Laplace approximated EM Microarray Analysis.</mixed-citation></ref><ref id="pone.0046736-Bar2"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Bar</surname><given-names>H</given-names></name>, <name><surname>Booth</surname><given-names>J</given-names></name>, <name><surname>Schifano</surname><given-names>E</given-names></name>, <name><surname>Wells</surname><given-names>MT</given-names></name> (<year>2010</year>) <article-title>Laplace Approximated EM Microarray Analysis: An Empirical Bayes Approach for Comparative Microarray Experiments</article-title>. <source>Statistical Science</source>
<volume>25</volume>: <fpage>388</fpage>&#x02013;<lpage>407</lpage>.</mixed-citation></ref><ref id="pone.0046736-Zeeberg1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Zeeberg</surname><given-names>BR</given-names></name>, <name><surname>Qin</surname><given-names>H</given-names></name>, <name><surname>Narasimhan</surname><given-names>S</given-names></name>, <name><surname>Sunshine</surname><given-names>M</given-names></name>, <name><surname>Cao</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>High-Throughput GoMiner, an &#x02018;industrial-strength&#x02019; integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID)</article-title>. <source>BMC Bioinformatics</source>
<volume>6</volume>: <fpage>168</fpage>.<pub-id pub-id-type="pmid">15998470</pub-id></mixed-citation></ref><ref id="pone.0046736-Saeed1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Saeed</surname><given-names>AI</given-names></name>, <name><surname>Bhagabati</surname><given-names>NK</given-names></name>, <name><surname>Braisted</surname><given-names>JC</given-names></name>, <name><surname>Liang</surname><given-names>W</given-names></name>, <name><surname>Sharov</surname><given-names>V</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>TM4 microarray software suite</article-title>. <source>Methods Enzymol</source>
<volume>411</volume>: <fpage>134</fpage>&#x02013;<lpage>193</lpage>.<pub-id pub-id-type="pmid">16939790</pub-id></mixed-citation></ref><ref id="pone.0046736-Saeed2"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Saeed</surname><given-names>AI</given-names></name>, <name><surname>Sharov</surname><given-names>V</given-names></name>, <name><surname>White</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Liang</surname><given-names>W</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>TM4: a free, open-source system for microarray data management and analysis</article-title>. <source>Biotechniques</source>
<volume>34</volume>: <fpage>374</fpage>&#x02013;<lpage>378</lpage>.<pub-id pub-id-type="pmid">12613259</pub-id></mixed-citation></ref><ref id="pone.0046736-Edgar1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Edgar</surname><given-names>R</given-names></name>, <name><surname>Domrachev</surname><given-names>M</given-names></name>, <name><surname>Lash</surname><given-names>AE</given-names></name> (<year>2002</year>) <article-title>Gene Expression Omnibus: NCBI gene expression and hybridization array data repository</article-title>. <source>Nucleic Acids Res</source>
<volume>30</volume>: <fpage>207</fpage>&#x02013;<lpage>210</lpage>.<pub-id pub-id-type="pmid">11752295</pub-id></mixed-citation></ref><ref id="pone.0046736-Chew1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Chew</surname><given-names>TW</given-names></name>, <name><surname>Jiang</surname><given-names>XY</given-names></name>, <name><surname>Yan</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Lusa</surname><given-names>AL</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Folate Intake, Mthfr Genotype, and Sex Modulate Choline Metabolism in Mice</article-title>. <source>Journal of Nutrition</source>
<volume>141</volume>: <fpage>1475</fpage>&#x02013;<lpage>1481</lpage>.<pub-id pub-id-type="pmid">21697299</pub-id></mixed-citation></ref><ref id="pone.0046736-Livak1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Livak</surname><given-names>KJ</given-names></name>, <name><surname>Schmittgen</surname><given-names>TD</given-names></name> (<year>2001</year>) <article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title>. <source>Methods</source>
<volume>25</volume>: <fpage>402</fpage>&#x02013;<lpage>408</lpage>.<pub-id pub-id-type="pmid">11846609</pub-id></mixed-citation></ref><ref id="pone.0046736-Song1"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Song</surname><given-names>L</given-names></name>, <name><surname>James</surname><given-names>SR</given-names></name>, <name><surname>Kazim</surname><given-names>L</given-names></name>, <name><surname>Karpf</surname><given-names>AR</given-names></name> (<year>2005</year>) <article-title>Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry</article-title>. <source>Anal Chem</source>
<volume>77</volume>: <fpage>504</fpage>&#x02013;<lpage>510</lpage>.<pub-id pub-id-type="pmid">15649046</pub-id></mixed-citation></ref><ref id="pone.0046736-Drewniak1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Drewniak</surname><given-names>A</given-names></name>, <name><surname>Tool</surname><given-names>ATJ</given-names></name>, <name><surname>Geissler</surname><given-names>J</given-names></name>, <name><surname>van Bruggen</surname><given-names>R</given-names></name>, <name><surname>van den Berg</surname><given-names>TK</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Toll-like receptor-induced reactivity and strongly potentiated IL-8 production in granulocytes mobilized for transfusion purposes</article-title>. <source>Blood</source>
<volume>115</volume>: <fpage>4588</fpage>&#x02013;<lpage>4596</lpage>.<pub-id pub-id-type="pmid">20354173</pub-id></mixed-citation></ref><ref id="pone.0046736-Grishman1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Grishman</surname><given-names>EK</given-names></name>, <name><surname>White</surname><given-names>PC</given-names></name>, <name><surname>Savani</surname><given-names>RC</given-names></name> (<year>2012</year>) <article-title>Toll-like receptors, the NLRP3 inflammasome, and interleukin-1beta in the development and progression of type 1 diabetes</article-title>. <source>Pediatr Res</source>
</mixed-citation></ref><ref id="pone.0046736-Mantovani1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Mantovani</surname><given-names>A</given-names></name>, <name><surname>Cassatella</surname><given-names>MA</given-names></name>, <name><surname>Costantini</surname><given-names>C</given-names></name>, <name><surname>Jaillon</surname><given-names>S</given-names></name> (<year>2011</year>) <article-title>Neutrophils in the activation and regulation of innate and adaptive immunity</article-title>. <source>Nat Rev Immunol</source>
<volume>11</volume>: <fpage>519</fpage>&#x02013;<lpage>531</lpage>.<pub-id pub-id-type="pmid">21785456</pub-id></mixed-citation></ref><ref id="pone.0046736-Dascher1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Dascher</surname><given-names>CC</given-names></name>, <name><surname>Brenner</surname><given-names>MB</given-names></name> (<year>2003</year>) <article-title>CD1 antigen presentation and infectious disease</article-title>. <source>Contrib Microbiol</source>
<volume>10</volume>: <fpage>164</fpage>&#x02013;<lpage>182</lpage>.<pub-id pub-id-type="pmid">12530326</pub-id></mixed-citation></ref><ref id="pone.0046736-Oldham1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Oldham</surname><given-names>KA</given-names></name>, <name><surname>Parsonage</surname><given-names>G</given-names></name>, <name><surname>Bhatt</surname><given-names>RI</given-names></name>, <name><surname>Wallace</surname><given-names>DM</given-names></name>, <name><surname>Deshmukh</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>T lymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6</article-title>. <source>Eur Urol</source>
<volume>61</volume>: <fpage>385</fpage>&#x02013;<lpage>394</lpage>.<pub-id pub-id-type="pmid">22079021</pub-id></mixed-citation></ref><ref id="pone.0046736-Stenstad1"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Stenstad</surname><given-names>H</given-names></name>, <name><surname>Ericsson</surname><given-names>A</given-names></name>, <name><surname>Johansson-Lindbom</surname><given-names>B</given-names></name>, <name><surname>Svensson</surname><given-names>M</given-names></name>, <name><surname>Marsal</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Gut-associated lymphoid tissue-primed CD4+ T cells display CCR9-dependent and -independent homing to the small intestine</article-title>. <source>Blood</source>
<volume>107</volume>: <fpage>3447</fpage>&#x02013;<lpage>3454</lpage>.<pub-id pub-id-type="pmid">16391017</pub-id></mixed-citation></ref><ref id="pone.0046736-Denoeud1"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Denoeud</surname><given-names>J</given-names></name>, <name><surname>Moser</surname><given-names>M</given-names></name> (<year>2011</year>) <article-title>Role of CD27/CD70 pathway of activation in immunity and tolerance</article-title>. <source>J Leukoc Biol</source>
<volume>89</volume>: <fpage>195</fpage>&#x02013;<lpage>203</lpage>.<pub-id pub-id-type="pmid">20699361</pub-id></mixed-citation></ref><ref id="pone.0046736-Koretzky1"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Koretzky</surname><given-names>GA</given-names></name>, <name><surname>Abtahian</surname><given-names>F</given-names></name>, <name><surname>Silverman</surname><given-names>MA</given-names></name> (<year>2006</year>) <article-title>SLP76 and SLP65: complex regulation of signalling in lymphocytes and beyond</article-title>. <source>Nat Rev Immunol</source>
<volume>6</volume>: <fpage>67</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">16493428</pub-id></mixed-citation></ref><ref id="pone.0046736-Qanungo1"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Qanungo</surname><given-names>S</given-names></name>, <name><surname>Mukherjea</surname><given-names>M</given-names></name> (<year>2000</year>) <article-title>Ontogenic profile of some antioxidants and lipid peroxidation in human placental and fetal tissues</article-title>. <source>Molecular and Cellular Biochemistry</source>
<volume>215</volume>: <fpage>11</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">11204445</pub-id></mixed-citation></ref><ref id="pone.0046736-Wang1"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Wang</surname><given-names>YP</given-names></name>, <name><surname>Walsh</surname><given-names>SW</given-names></name>, <name><surname>Guo</surname><given-names>JD</given-names></name>, <name><surname>Zhang</surname><given-names>JY</given-names></name> (<year>1991</year>) <article-title>Maternal Levels of Prostacyclin, Thromboxane, Vitamin-E, and Lipid Peroxides Throughout Normal-Pregnancy</article-title>. <source>American Journal of Obstetrics and Gynecology</source>
<volume>165</volume>: <fpage>1690</fpage>&#x02013;<lpage>1694</lpage>.<pub-id pub-id-type="pmid">1750461</pub-id></mixed-citation></ref><ref id="pone.0046736-Vidali1"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Vidali</surname><given-names>M</given-names></name>, <name><surname>Stewart</surname><given-names>SF</given-names></name>, <name><surname>Albano</surname><given-names>E</given-names></name> (<year>2008</year>) <article-title>Interplay between oxidative stress and immunity in the progression of alcohol-mediated liver injury</article-title>. <source>Trends in Molecular Medicine</source>
<volume>14</volume>: <fpage>63</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">18222109</pub-id></mixed-citation></ref><ref id="pone.0046736-Lamb1"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Lamb</surname><given-names>FS</given-names></name>, <name><surname>Hook</surname><given-names>JS</given-names></name>, <name><surname>Hilkin</surname><given-names>BM</given-names></name>, <name><surname>Huber</surname><given-names>JN</given-names></name>, <name><surname>Volk</surname><given-names>AP</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Endotoxin priming of neutrophils requires endocytosis and NADPH oxidase-dependent endosomal reactive oxygen species</article-title>. <source>J Biol Chem</source>
<volume>287</volume>: <fpage>12395</fpage>&#x02013;<lpage>12404</lpage>.<pub-id pub-id-type="pmid">22235113</pub-id></mixed-citation></ref><ref id="pone.0046736-Cooke1"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Cooke</surname><given-names>MS</given-names></name>, <name><surname>Evans</surname><given-names>MD</given-names></name>, <name><surname>Dizdaroglu</surname><given-names>M</given-names></name>, <name><surname>Lunec</surname><given-names>J</given-names></name> (<year>2003</year>) <article-title>Oxidative DNA damage: mechanisms, mutation, and disease</article-title>. <source>FASEB J</source>
<volume>17</volume>: <fpage>1195</fpage>&#x02013;<lpage>1214</lpage>.<pub-id pub-id-type="pmid">12832285</pub-id></mixed-citation></ref><ref id="pone.0046736-Collins1"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Collins</surname><given-names>AR</given-names></name> (<year>2004</year>) <article-title>The comet assay for DNA damage and repair: principles, applications, and limitations</article-title>. <source>Mol Biotechnol</source>
<volume>26</volume>: <fpage>249</fpage>&#x02013;<lpage>261</lpage>.<pub-id pub-id-type="pmid">15004294</pub-id></mixed-citation></ref><ref id="pone.0046736-Kim1"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Kim</surname><given-names>TH</given-names></name>, <name><surname>Barrera</surname><given-names>LO</given-names></name>, <name><surname>Zheng</surname><given-names>M</given-names></name>, <name><surname>Qu</surname><given-names>CX</given-names></name>, <name><surname>Singer</surname><given-names>MA</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>A high-resolution map of active promoters in the human genome</article-title>. <source>Nature</source>
<volume>436</volume>: <fpage>876</fpage>&#x02013;<lpage>880</lpage>.<pub-id pub-id-type="pmid">15988478</pub-id></mixed-citation></ref><ref id="pone.0046736-Chaussabel1"><label>43</label><mixed-citation publication-type="journal">
<name><surname>Chaussabel</surname><given-names>D</given-names></name>, <name><surname>Pascual</surname><given-names>V</given-names></name>, <name><surname>Banchereau</surname><given-names>J</given-names></name> (<year>2010</year>) <article-title>Assessing the human immune system through blood transcriptomics</article-title>. <source>BMC Biol</source>
<volume>8</volume>: <fpage>84</fpage>.<pub-id pub-id-type="pmid">20619006</pub-id></mixed-citation></ref><ref id="pone.0046736-Pascual1"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Pascual</surname><given-names>V</given-names></name>, <name><surname>Chaussabel</surname><given-names>D</given-names></name>, <name><surname>Banchereau</surname><given-names>J</given-names></name> (<year>2010</year>) <article-title>A genomic approach to human autoimmune diseases</article-title>. <source>Annu Rev Immunol</source>
<volume>28</volume>: <fpage>535</fpage>&#x02013;<lpage>571</lpage>.<pub-id pub-id-type="pmid">20192809</pub-id></mixed-citation></ref><ref id="pone.0046736-Talwar1"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Talwar</surname><given-names>S</given-names></name>, <name><surname>Munson</surname><given-names>PJ</given-names></name>, <name><surname>Barb</surname><given-names>J</given-names></name>, <name><surname>Fiuza</surname><given-names>C</given-names></name>, <name><surname>Cintron</surname><given-names>AP</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Gene expression profiles of peripheral blood leukocytes after endotoxin challenge in humans</article-title>. <source>Physiol Genomics</source>
<volume>25</volume>: <fpage>203</fpage>&#x02013;<lpage>215</lpage>.<pub-id pub-id-type="pmid">16403844</pub-id></mixed-citation></ref></ref-list></back></article>